Immune aging clock pinpoints RUNX1 as a brake on T cell senescence
A single-cell immune aging clock built from 1.2M blood cells flags RUNX1 as a regulator of T cell aging, and restoring it eased senescence in aged CD8+ T cells.
Résumé
Researchers built a human immune aging clock using single-cell multi-omics data from nearly 1.2 million peripheral blood mononuclear cells across 230 people. T cell gene expression was the strongest predictor of immune age, capturing known hallmarks like loss of naive T cells and contraction of T cell clones. The model highlighted the transcription factor RUNX1, whose expression falls with age in T cells. Deleting RUNX1 in young T cells triggered senescence, while restoring it in aged CD8+ T cells reduced senescent features in lab cultures and in living animal models. The work offers a quantitative way to measure immunosenescence and nominates RUNX1 as a candidate target for rejuvenating aged immunity. These findings are preclinical, and no human treatment has been tested.
Résumé détaillé
Immune aging, or immunosenescence, is thought to drive aging of the whole body, raising infection risk, weakening vaccine responses, and contributing to chronic disease. But people age immunologically at different rates, and measuring that variation well enough to find drug targets has been difficult.
The team built an immune aging clock from single-cell multi-omics data covering nearly 1.2 million peripheral blood mononuclear cells from 230 individuals. The model was designed to map each person's immune age with cell-level resolution.
T cell transcriptomes were the most informative predictors of immune age. The clock reflected recognized hallmarks of T cell aging, including loss of naive cells and clonal contraction. Analysis of the model pointed to the transcription factor RUNX1, whose expression declines with age in T cells, as a central regulator. In functional experiments, deleting RUNX1 in young T cells induced senescence. Restoring RUNX1 in aged CD8+ T cells alleviated senescent phenotypes both in vitro and in vivo.
The study offers two things: a quantitative tool for assessing immunosenescence, and RUNX1 as a candidate target for rejuvenating aged immunity. If validated, similar clocks could help track whether interventions slow immune aging, and RUNX1-directed strategies could inform T cell therapies or approaches to restoring immune function in older adults.
Caveats apply. This summary is based only on the abstract, so details on cohort composition, age range, validation, and the in vivo models are unavailable. RUNX1 also has roles in blood development and cancer, so safety of boosting it is unknown. The findings are preclinical and do not yet show clinical benefit.
Principales conclusions
- An immune aging clock was built from single-cell data on nearly 1.2 million PBMCs from 230 individuals.
- T cell transcriptomes were the key predictors of immune age, reflecting naive cell loss and clonal contraction.
- RUNX1 expression declines with age in T cells and was identified as a central regulator of T cell aging.
- Deleting RUNX1 in young T cells induced senescence.
- Restoring RUNX1 in aged CD8+ T cells reduced senescent phenotypes in vitro and in vivo.
Méthodologie
The authors trained an immune aging clock on single-cell multi-omics data from nearly 1.2 million PBMCs from 230 people, then used it to identify regulators of aging. RUNX1 was tested through deletion in young T cells and restoration in aged CD8+ T cells, in vitro and in vivo.
Limites de l'étude
Only the abstract was available, so cohort demographics, clock validation, and in vivo model details are unclear. RUNX1 is also involved in hematopoiesis and malignancy, so safety of increasing its activity is unproven. Findings are preclinical, and the clock's ability to predict health outcomes in people is not shown in the abstract.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :